LEUVEN, Belgium, November 20, 2013 /PRNewswire/ -- Canada is the first market launch for JETREA®outside the US and Europe ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA) in Canada. Canada is the first market where JETREA® has been launched outside the US and Europe. Symptomatic VMA is estimated to affect up to 15,000 people in Canada each year . Health Canada approved JETREA ® on August 13, 2013 following priority review. Alcon, a division of Novartis, acquired the rights to commercialize JETREA ® outside the United States in March 2012. It launched the drug in the UK, its first European market, in April, followed by launches in Germany, Denmark, Finland, Norway and Sweden. ThromboGenics is commercializing the drug in the US and launched JETREA ® in the US in mid-January 2013 where it is approved for the treatment of patients with symptomatic vitreomacular adhesion (VMA). Dr Patrik De Haes, CEO of ThromboGenics, says:"The launch of JETREA®in Canada, the first market outside the US and Europe, is an another important step in the global roll out of this innovative new drug for the treatment of symptomatic VMA. This is a condition where early pharmacological treatment is being seen as increasingly important in potentially preventing patients'loss of visual acuity which negatively impacts on their ability to carry out everyday tasks. We are looking forward to working with Alcon as it continues to roll outJETREA®in other European and Rest of the World markets." JETREA ® contains the active substance ocriplasmin. It is administered through a one-time, single intravitreal injection to treat adults with symptomatic VMA. Symptomatic VMA is an age-related progressive, sight-threatening condition. It is caused by the vitreous having an abnormally strong attachment to the central part of the retina (the light sensitive membrane at the back of the eye). The macula provides central vision that is needed for everyday tasks such as driving, reading and recognizing faces.